Infections of the respiratory tract remain one of the leading causes of death in the United States [1] . The cost burden for bacterial infections of the upper and lower respiratory tract is tremendous; the cost alone of treating patients with communityacquired pneumonia (CAP) has recently been estimated to be close to $10 billion (US) [2] . In addition, the emergence of drugresistant pathogens presents a challenge to infectious disease clinicians. Several common respiratory tract pathogens, including Streptococcus pneumoniae and Haemophilus influenzae, have shown a progressive tendency to develop resistance to both b-lactam and non-b-lactam antibiotics.
National and international multicenter surveillance programs have been tracking the prevalence and patterns of antimicrobial resistance among respiratory tract pathogens. At the local level, these surveillance programs can be used to help guide therapeutic decisions. Newer antimicrobials for the treatment of CAP, such as the newer fluoroquinolones, offer significant advantages over existing agents, including a broader spectrum of activity, improved safety, higher bioavailability, and reduced resistance potential. These agents may also offer shorter courses of therapy, enhanced patient compliance, and potential economic savings. The newer fluoroquinolones, which have been engineered to exhibit enhanced gram-positive activity while maintaining gram-negative activity, are frequently active against resistant bacterial strains.
There are 2 means by which bacteria can become resistant to fluoroquinolones: mutations in 1 or both of fluoroquinolone enzyme targets and overexpression of multidrug efflux pumps. Each fluoroquinolone has different relative activities against the enzymes, which may also vary with the type of pathogen. Enzyme targets may be more susceptible to the newer fluoroquinolones, thereby decreasing the likelihood of bacterial resistance. Knowledge of these variations is important in selecting the appropriate dosage regimen for clinical care.
The discovery of multiple drug-resistant S. pneumoniae (DRSP), which is defined as having reduced susceptibility to у2 antibacterials, has heightened the interest in fluoroquinolones. Some formerly potent antipneumococcal agents, such as the b- lactams and macrolides, are not always effective against DRSP, whereas the newer fluoroquinolones show good activity; these agents are highly effective against the pneumococcus, with few reports of resistance strains.
Fluoroquinolones are also active against pathogens causing atypical pneumonia. These organisms, Legionella species, Chlamydia pneumoniae, and Mycoplasma pneumoniae, cause infections that are difficult to diagnose and may account for a large percentage of CAP pathogens where an etiologic diagnosis remains undetermined. Because few diagnostic tools are available to identify these so-called atypicals, fluoroquinolones are an excellent option for the empirical treatment of patients with CAP.
The threat of antibiotic-resistant pneumococci in meningitis presents another challenge to infectious disease clinicians. Limited clinical experience and investigations using animal models have identified newer fluoroquinolones, such as gatifloxacin, as good candidates for treatment of meningitis. The possibility of adverse effects in children, such as chondrotoxicity and neurologic events, requires further investigation before using such agents in this population.
Resistance to antibiotics is often the result of suboptimal dosing strategies. To identify optimal antimicrobial dosages, the relationship between pharmacokinetic (PK) and pharmacodynamic parameters has been correlated with clinical and microbiologic outcome. Dosing regimens that consider both the PK of the antibacterial agent and the susceptibility of clinical pathogens to that agent should help control antibacterial resistance in the community.
The challenge ahead is to expand our knowledge of antimicrobial resistance and learn how to minimize its occurrence. Physicians will need to use appropriate therapies to optimize care of individual patients while managing the potential selection of antibacterial resistance in the community. Each of the topics mentioned previously is explored in this supplement. The presentations examine, in the context of respiratory tract infections, how this challenge can be addressed and the role of newer fluoroquinolones.
